| 3304 |
2243: Succinate Accumulation |
798: Inhibition, Prolyl hydroxylases |
Jul 18, 2024 |
Jul 18, 2024 |
1 AOP
|
| 2866 |
2118: SDH, inhibited |
2120: Superoxide generation, increased |
Apr 3, 2023 |
May 4, 2023 |
1 AOP
|
| 3233 |
2118: SDH, inhibited |
1446: Decrease, Coupling of OXPHOS |
May 28, 2024 |
May 28, 2024 |
1 AOP
|
| 3302 |
2118: SDH, inhibited |
2243: Succinate Accumulation |
Jul 18, 2024 |
Jul 18, 2024 |
2 AOPs
|
| 3554 |
2118: SDH, inhibited |
177: Increase, Mitochondrial dysfunction |
Aug 1, 2025 |
Aug 1, 2025 |
1 AOP
|
| 3273 |
2120: Superoxide generation, increased |
1392: Increase, Oxidative Stress |
Jul 4, 2024 |
Jul 4, 2024 |
1 AOP
|
| 1817 |
1565: Suppressed AP-1 |
1567: Suppressed DC activation |
Dec 25, 2018 |
Dec 25, 2018 |
None
|
| 1819 |
1567: Suppressed DC activation |
1568: Impaired antigen presentation |
Dec 25, 2018 |
Dec 25, 2018 |
None
|
| 1826 |
1573: Suppressed MyD88 |
986: Impairment of TDAR |
Jan 6, 2019 |
Jan 6, 2019 |
None
|
| 1870 |
1573: Suppressed MyD88 |
202: Inhibition, Nuclear factor kappa B (NF-kB) |
Mar 12, 2019 |
Mar 12, 2019 |
None
|
| 1818 |
1566: Suppressed NF-kB |
1567: Suppressed DC activation |
Dec 25, 2018 |
Dec 25, 2018 |
None
|
| 2001 |
1702: Suppression of T cell activation |
202: Inhibition, Nuclear factor kappa B (NF-kB) |
Nov 17, 2019 |
Nov 17, 2019 |
None
|
| 2004 |
1702: Suppression of T cell activation |
986: Impairment of TDAR |
Nov 17, 2019 |
Mar 2, 2023 |
None
|
| 2927 |
1702: Suppression of T cell activation |
1700: Impaired IL-1R1 signaling |
May 24, 2023 |
May 24, 2023 |
None
|
| 2928 |
1702: Suppression of T cell activation |
984: Impairment, T-cell dependent antibody response |
May 24, 2023 |
May 25, 2023 |
1 AOP
|
| 2027 |
1718: Suppression of IL-4 production |
1719: Impairment, TDAR |
Jan 5, 2020 |
Apr 4, 2021 |
1 AOP
|
| 3684 |
2385: Suppression of Keap1 cysteine oxidation |
1417: NFE2/Nrf2 repression |
Nov 4, 2025 |
Nov 4, 2025 |
1 AOP
|
| 2026 |
1717: Suppression of STAT5 binding to cytokine gene promoters |
1718: Suppression of IL-4 production |
Jan 5, 2020 |
Mar 30, 2021 |
1 AOP
|
| 476 |
456: Suppression, Constitutive androstane receptor, NR1l3 |
167: Activation, LXR |
Nov 29, 2016 |
Dec 3, 2016 |
1 AOP
|
| 477 |
456: Suppression, Constitutive androstane receptor, NR1l3 |
228: demethylation, PPARg promoter |
Nov 29, 2016 |
Dec 3, 2016 |
1 AOP
|
| 1086 |
1046: Suppression, Estrogen receptor (ER) activity |
1056: Decrease, E2 blood concentrations at hypothalamus |
Nov 29, 2016 |
Dec 3, 2016 |
1 AOP
|
| 2580 |
1046: Suppression, Estrogen receptor (ER) activity |
1047: Increased, secretion of GnRH from hypothalamus |
Feb 26, 2022 |
Mar 1, 2022 |
1 AOP
|
| 1255 |
1202: Suppression, IL-2 and IL-4 production |
979: Interference, nuclear localization of NFAT |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 1510 |
1202: Suppression, IL-2 and IL-4 production |
984: Impairment, T-cell dependent antibody response |
May 19, 2017 |
Jun 27, 2021 |
1 AOP
|
| 570 |
403: Suppression, Immune system |
576: Increased, Viral susceptibility |
Nov 29, 2016 |
Dec 3, 2016 |
2 AOPs
|